Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Mod Rheumatol ; 32(2): 358-364, 2022 Feb 28.
Article in English | MEDLINE | ID: mdl-33896348

ABSTRACT

OBJECTIVES: We retrospectively compared the therapeutic effects of combination therapy with prednisolone (PSL) and oral tacrolimus (TAC) or azathioprine (AZA) on progressive interstitial pneumonia with systemic sclerosis (SSc-PIP). METHODS: The effects of PSL (0.2-0.5 mg/kg/day) and TAC (3 mg/day) or AZA (1-2 mg/kg/day) therapies (n = 18) were evaluated for short (12 months) and long (36 months or more) periods. RESULTS: In the short period, IP improved in 6 and 5 patients and was stable in 12 and 13 patients in the TAC and AZA groups, respectively. In the long period, 11 patients were followed up in the TAC group and 12 in the AZA group. IP improved in 4 and 2 patients and was stable in seven and nine in the TAC and AZA groups, respectively. The rates of evolution of total fibrosis score, and those corrected by disease duration for the long period, in the TAC group were significantly lower than those in the AZA group (p = .017 and .025, respectively). CONCLUSION: The inhibitory effect of PSL and TAC combination therapy on the progression of fibrosis in SSc-PIP may be superior to that of PSL and AZA in the long period.


Subject(s)
Lung Diseases, Interstitial , Scleroderma, Systemic , Azathioprine/therapeutic use , Drug Therapy, Combination , Fibrosis , Humans , Immunosuppressive Agents/therapeutic use , Lung Diseases, Interstitial/complications , Lung Diseases, Interstitial/drug therapy , Prednisolone/therapeutic use , Retrospective Studies , Scleroderma, Systemic/complications , Scleroderma, Systemic/drug therapy , Tacrolimus/therapeutic use , Treatment Outcome
2.
Clin Respir J ; 12(7): 2235-2241, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29633527

ABSTRACT

OBJECTIVE: To identify a predictor of relapse in interstitial pneumonia (IP) in patients with anti-aminoacyl tRNA synthetase antibodies-positive dermatomyositis (ARS-DMIP). METHODS: This retrospective cohort study comprised 27 ARS-DMIP patients. We compared clinical and laboratory findings between the relapse and non-relapse groups during 2 years after treatment initiation to find predictors of relapse in IP. Candidate predictors were further assessed by analysing the relationship with the relapse of IP. RESULTS: One patient with ARS-DMIP died. About 7 (26.9%) of the remaining 26 patients with ARS-DMIP had a relapse of IP. We found that the levels of serum Krebs von den Lungen-6 (KL-6) in the relapse group were significantly higher than those in the non-relapse group at the time points before treatment (P = .046) and after treatments, including 6 (P = .004), 12 (P = .013), 18 (P = .003) and 24 months (P < .001). The KL-6 values that maximised the area under the ROC curve were 2347 U/mL before treatment, 622 U/mL after 6 months and 468 U/mL after 12 months. The relapse rates after 104 weeks were significantly higher in patients with KL-6 levels ≥2400 U/mL before treatment (P = .014), ≥600 ng/mL after 6 months (P < .005) and ≥470 U/mL after 12 months (P = .010). CONCLUSION: These findings suggest that the levels of KL-6 before and after treatment in ARS-DMIP may represent the disease activity of IP, and they may be useful as the predictor of relapse in IP in patients with ARS-DMIP.


Subject(s)
Amino Acyl-tRNA Synthetases/immunology , Antibodies/metabolism , Dermatomyositis/complications , Lung Diseases, Interstitial/blood , Mucin-1/blood , Adult , Aged , Area Under Curve , Biomarkers/blood , Dermatomyositis/immunology , Female , Humans , Male , Middle Aged , Recurrence , Retrospective Studies
3.
Mod Rheumatol ; 28(6): 1009-1015, 2018 Nov.
Article in English | MEDLINE | ID: mdl-29442534

ABSTRACT

OBJECTIVES: We retrospectively investigated efficacy and safety of combination therapy with prednisolone (PSL) and tacrolimus (TAC) for progressive interstitial pneumonitis with systemic sclerosis (SSc-PIP). METHODS: We studied 11 patients with SSc-PIP who received combination therapy with PSL (0.5 mg/kg/d) and TAC (3 mg/d). RESULTS: Baseline Hugh-Jones grades were I, II, III, and IV in 2, 6, 2, and 1 patients, respectively. Krebs von den Lungen-6 (KL-6) values were elevated to 914 (range 300-2614) U/mL. % Diffusing capacity of carbon monoxide (%DLco) remarkably decreased to 47.4 (range 9.7-64.4) %. All patients were alive at 1 year after therapy. In response to treatment, interstitial pneumonia (IP) improved in three patients, stable in seven patients, and deteriorated in one patient. Total ground-glass opacity (GGO) score improved (p = .005). No significant changes occurred in values of KL-6, % forced vital capacity (%FVC), and %DLco. Presently, all seven patients who could be followed up were alive. IP improved in three patients and stable in four patients. Total GGO score improved (p = .016). KL-6, %FVC, and %DLco did not change. Mild cytomegalovirus or herpes zoster infection occurred in two patients. Grade I renal injuries were observed in three and one patient at 1 year and present, respectively. CONCLUSION: Combination therapy with PSL and TAC appeared to be well tolerated and effective in suppressing the disease activity of SSc-PIP.


Subject(s)
Lung Diseases, Interstitial , Prednisolone/administration & dosage , Scleroderma, Systemic , Tacrolimus/administration & dosage , Administration, Oral , Adult , Aged , Disease Progression , Drug Therapy, Combination/methods , Female , Humans , Japan/epidemiology , Lung Diseases, Interstitial/diagnosis , Lung Diseases, Interstitial/drug therapy , Lung Diseases, Interstitial/epidemiology , Male , Middle Aged , Respiratory Function Tests/methods , Retrospective Studies , Scleroderma, Systemic/diagnosis , Scleroderma, Systemic/drug therapy , Scleroderma, Systemic/epidemiology , Severity of Illness Index , Vital Capacity
4.
Nihon Rinsho Meneki Gakkai Kaishi ; 40(5): 382-386, 2017.
Article in Japanese | MEDLINE | ID: mdl-29238021

ABSTRACT

  A 51-year-old man was detected nasal bleeding, multiple pulmonary nodule and mass, urinalysis abnormality, renal involvement and high titer of proteinase 3-anti-neutrophil cytoplasmic antibody (PR3-ANCA), and was suspected of granulomatosis with polyangiitis and initiated with steroid pulse therapy. On the day after the start of steroid pulse therapy, generalized peritonitis due to ileal perforation occurred, and emergency ileectomy and peritonitis surgery were performed. Induction therapy with steroid pulse therapy, plasma exchange and intravenous cyclophosphamide therapy (IVCY) and maintenance therapy with glucocorticoid and azathioprine led to good therapeutic outcomes. Gastrointestinal perforation in GPA is a rare complication, and we examined the clinical features, treatment contents, and prognosis of GPA with gastrointestinal perforation from this case and previous reports. Lung involvements were complicated in all reported cases. Gastrointestinal perforations in GPA were frequent in the small intestine, occurred just before and immediately after the start of treatment, and were severe involvement with poor prognosis because of the high mortality rate (46.7%). The frequency of ear, nose and upper respiratory tract lesions in the surviving group was significantly higher than in the dead group (survival 87.5%, death 28.3%, P = 0.041). IVCY were more frequently used in the surviving group (62.5%) than the death group (16.7%), but it was not significantly. GPA complicated with gastrointestinal perforation is a severe condition with poor prognosis, but there is a possibility to improve prognosis by early diagnosis and early initiation of strong treatment.


Subject(s)
Granulomatosis with Polyangiitis/complications , Granulomatosis with Polyangiitis/therapy , Ileum , Intestinal Perforation/etiology , Plasma Exchange , Antibodies, Antineutrophil Cytoplasmic/blood , Azathioprine/administration & dosage , Biomarkers/blood , Cyclophosphamide/administration & dosage , Early Diagnosis , Granulomatosis with Polyangiitis/diagnosis , Humans , Intestinal Perforation/surgery , Male , Methylprednisolone/administration & dosage , Middle Aged , Myeloblastin/immunology , Prognosis , Pulse Therapy, Drug
SELECTION OF CITATIONS
SEARCH DETAIL
...